Hims & Hers Health (NYSE:HIMS) Announces Earnings Results

Hims & Hers Health (NYSE:HIMS) released its earnings results on Monday. The company reported ($0.40) EPS for the quarter, missing the consensus estimate of $0.04 by ($0.44), FiscalAI reports. The firm had revenue of $608.10 million during the quarter, compared to the consensus estimate of $616.88 million. Hims & Hers Health had a net margin of 5.47% and a return on equity of 22.48%.

Hims & Hers Health Price Performance

Shares of HIMS traded up $0.85 during mid-day trading on Monday, reaching $29.12. The company had a trading volume of 54,698,765 shares, compared to its average volume of 33,104,969. The company has a market capitalization of $6.64 billion, a price-to-earnings ratio of 57.10, a P/E/G ratio of 3.85 and a beta of 2.43. The company has a debt-to-equity ratio of 1.80, a quick ratio of 1.70 and a current ratio of 1.90. The company’s 50 day simple moving average is $22.56 and its 200 day simple moving average is $29.75. Hims & Hers Health has a 1-year low of $13.74 and a 1-year high of $70.43.

Insider Activity at Hims & Hers Health

In related news, insider Soleil Boughton sold 9,463 shares of the stock in a transaction that occurred on Monday, April 20th. The shares were sold at an average price of $30.00, for a total value of $283,890.00. Following the completion of the transaction, the insider owned 299,368 shares of the company’s stock, valued at $8,981,040. This represents a 3.06% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Irene Becklund sold 5,529 shares of the firm’s stock in a transaction that occurred on Tuesday, March 17th. The shares were sold at an average price of $24.69, for a total transaction of $136,511.01. Following the completion of the sale, the insider owned 8,752 shares in the company, valued at $216,086.88. This represents a 38.72% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 204,857 shares of company stock valued at $5,285,706 in the last quarter. 11.76% of the stock is owned by company insiders.

Institutional Investors Weigh In On Hims & Hers Health

Several hedge funds have recently modified their holdings of HIMS. United Capital Financial Advisors LLC acquired a new position in Hims & Hers Health in the 3rd quarter worth about $369,000. Amundi acquired a new position in shares of Hims & Hers Health in the fourth quarter valued at approximately $341,000. First Citizens Bank & Trust Co. bought a new position in Hims & Hers Health in the 4th quarter valued at approximately $311,000. SummitTX Capital L.P. boosted its position in Hims & Hers Health by 106.9% during the 4th quarter. SummitTX Capital L.P. now owns 9,437 shares of the company’s stock worth $306,000 after buying an additional 4,876 shares during the period. Finally, Orion Porfolio Solutions LLC boosted its position in Hims & Hers Health by 18.4% during the 4th quarter. Orion Porfolio Solutions LLC now owns 8,745 shares of the company’s stock worth $284,000 after buying an additional 1,359 shares during the period. Institutional investors and hedge funds own 63.52% of the company’s stock.

Analysts Set New Price Targets

HIMS has been the topic of several analyst reports. Morgan Stanley reduced their price target on shares of Hims & Hers Health from $40.00 to $21.00 and set an “equal weight” rating on the stock in a research report on Tuesday, February 24th. Citigroup upgraded shares of Hims & Hers Health from a “sell” rating to a “neutral” rating and boosted their price objective for the company from $13.25 to $24.00 in a research report on Tuesday, March 10th. Weiss Ratings restated a “hold (c)” rating on shares of Hims & Hers Health in a research note on Friday, March 27th. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and issued a $25.00 target price on shares of Hims & Hers Health in a report on Tuesday, May 5th. Finally, Evercore set a $24.00 price target on Hims & Hers Health in a report on Tuesday, February 24th. Four investment analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Hims & Hers Health currently has an average rating of “Hold” and a consensus target price of $31.86.

Trending Headlines about Hims & Hers Health

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Hims & Hers raised its outlook for FY 2026 revenue to $2.8 billion-$3.0 billion, ahead of the $2.7 billion consensus, suggesting management sees continued strong demand for its telehealth and digital care offerings.
• Positive Sentiment: The company also guided Q2 2026 revenue to $680 million-$700 million, above Wall Street’s $643.8 million estimate, which may help offset concerns from the latest earnings miss.
• Neutral Sentiment: Hims & Hers continues to expand its digital healthcare platform with new care offerings, including labs, menopause and testosterone care, along with broader international and GLP-1-related initiatives. Article: Hims & Hers Expands Digital Healthcare Platform via New Care Offerings
• Negative Sentiment: First-quarter results disappointed, with EPS of -$0.40 versus expectations for $0.04 and revenue of $608.1 million versus $616.9 million expected, which explains the pressure on the stock.
• Negative Sentiment: Investor reaction has been cautious after the earnings release, with coverage noting that shares are falling because the quarter came in below Wall Street expectations. Article: Hims & Hers Stock Sinks. Why Earnings Offered Wall Street A Big Surprise.

About Hims & Hers Health

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.